CLEC1B抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07202(CLEC1B Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07202(CLEC1B Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The CLEC1B (C-type lectin domain family 1 member B) antibody targets a transmembrane protein encoded by the CLEC1B gene, also known as CLEC-2. This protein belongs to the C-type lectin receptor family, characterized by carbohydrate-recognition domains that mediate calcium-dependent ligand binding. CLEC1B is primarily expressed on platelets, myeloid cells, and some endothelial cells. It plays a critical role in platelet activation and thrombosis by interacting with its ligand, podoplanin (PDPN), a glycoprotein overexpressed in certain cancers and lymphatic endothelial cells. This interaction is essential for maintaining vascular integrity and regulating lymphatic development.

CLEC1B antibodies are valuable tools for studying platelet function, tumor metastasis (as PDPN-CLEC1B binding facilitates cancer cell invasion), and immune responses. Researchers use these antibodies in techniques like flow cytometry, immunohistochemistry, and Western blotting to detect CLEC1B expression or inhibit its activity in experimental models. Dysregulation of CLEC1B signaling has been implicated in thrombotic disorders, tumor progression, and inflammatory diseases. Recent studies explore therapeutic potential, such as blocking CLEC1B-PDPN interactions to prevent cancer metastasis or thrombosis. However, its dual role in hemostasis and immunity requires careful evaluation to balance efficacy and safety in clinical applications.